| Literature DB >> 22090264 |
Jan Van Zundert1, Pascal Vanelderen, Alfons Kessels, Maarten van Kleef.
Abstract
Pain originating from the lumbar facet joints is estimated to represent about 15% of all low back pain complaints. The diagnostic block is considered to be a valuable tool for confirming facetogenic pain. It was demonstrated that a block of the ramus medialis of the ramus dorsalis is preferred over an intra-articular injection. The outcome of the consequent radiofrequency treatment is not different in patients reporting over 80% pain relief after the diagnostic block than in those who have between 50% and 79% pain relief. There is one well-conducted comparative trial assessing the value of one or two controlled diagnostic blocks to none. The results of the seven randomized trials on the use of radiofrequency treatment of facet joint pain demonstrate that good patient selection is imperative for good clinical outcome. Therefore, we suggest one block of the ramus medialis of the ramus dorsalis before radiofrequency treatment.Entities:
Mesh:
Year: 2012 PMID: 22090264 PMCID: PMC3258411 DOI: 10.1007/s11916-011-0237-8
Source DB: PubMed Journal: Curr Pain Headache Rep ISSN: 1534-3081
Use of diagnostic blocks in the randomized controlled trials
| Study | Block | Fluoroscopy/dye | Levels | Uni- bilateral | Patients screened/included, | Duration of pain | Products | Evaluation | Cut-off | |
|---|---|---|---|---|---|---|---|---|---|---|
| Type |
| |||||||||
| Gallagher et al. [ | In and around joint | 1 | Yes/no info | ? | ? | 60/41 | > 3 months | Bupivacaine 0.5%, 0.5 mL | Pain relief over 12 h | Clear and equivocal pain relief |
| van Kleef et al. [ | Posterior primary ramus | 1 | Yes/no info | Min 3 | Symptom guided | 256/32 | > 12 months | Lidocaine 1%, 0.75 mL | Patient scores pain relief on a four-step Likert scale | 50% pain reduction |
| L3, L4, L5 | ||||||||||
| Leclaire et al. [ | Intraarticular | 1 | Yes/yes | ? | ? | 138/15 | > 6 months | Lidocaine 2%, 0.5 mL; triamcinolone, 40 mg, 0.5 mL | Patient assessment of pain relief during 1 week | Min 24 h “significant” pain relief |
| van Wijk et al. [ | Intraarticular | 1 | Yes/yes | 2 | Symptom guided | 76/70 | > 3 months | Lidocaine 2%, 0.25–0.5 mL | VAS 30 min postprocedure | 50% pain reduction |
| Th12-L2 | ||||||||||
| L2-L4 | ||||||||||
| L4-S1 | ||||||||||
| Tekin et al. [ | MBB | 1 | Yes/yes | 3 | Symptom guided | 462/81 | > 6 months | Lidocaine 2%, 0.3 mL | Patient | 50% pain reduction |
| L3, L4, L5 | ||||||||||
| Kroll et al. [ | MBB | 2 | Yes/Bogduk technique | Min 2 | ? | ? | > 6 months | Bupivacaine 0.5%, 1 mL | Patient 3 h postprocedure | 50% pain reduction after two blocks |
| ? | ||||||||||
| Nath et al. [ | MBB | 2–3 | Yes/Bogduk technique | Min 2 | Symptom guided | ? | > 1 month | Screening: bupivacaine 0.5%, 1 mL | Patient reported reduction of a consistent component of pain followed for 6 h | 80% pain reduction after each block for duration of action of LA |
| Standard targets | ||||||||||
| Lidocaine, bupivacaine | ||||||||||
?—no information provided; LA—local anesthetic; MBB—medial branch block; Min—minimum; VAS—visual analogue scale
Assessment details and outcomes of the seven randomized controlled trials
| Study | Treatments | Pts screened, | Pts included, | Groups assessed, | Parameters | Time | Outcome |
|---|---|---|---|---|---|---|---|
| Gallagher et al. [ | RF vs sham | 64 | 41 | Resp block, RF: 18; resp block, sham: 12; no resp block, RF: 6; no resp block, sham: 5 | VAS; McGill pain questionnaire | 1 and 6 months | Sign. improvement in VAS and McGill 1 and 6 months after RF vs sham in responders to block. No sign. difference in nonresponders to block |
| van Kleef et al. [ | RF vs sham | 264 | 31 | RF: 15; sham: 16 | VAS high and low; GPE; impairment; analgesic intake; ODI | 8 weeks; 3, 6, and 12 months | 8 weeks sign. higher improvement of VAS, GPE, ODI, and impairment. At 3, 6, and 12 months, higher number of pts with successful treatment outcome in RF group |
| Leclaire et al. [ | RF vs sham | 76 | 70 | RF: 36; sham: 34 | Roland Morris questionnaire; ODI | 4 and 12 weeks | RM better in RF group at 4 weeks. No difference in ODI. At 12 weeks no difference |
| van Wijk et al. [ | RF vs sham | 462 | 81 | RF: 44; sham: 41 | Combined outcome: median and max pain intensity; daily activities; analgesic intake; GPE; SF-36 | 3 months | Combined outcome no difference. GPE better in RF group |
| Tekin et al. [ | RF, PRF, sham | No info | 60 | RF: 20; PRF: 20; sham: 20 | VAS; ODI | Immediately postprocedure, 3, 6, 12 months | Three groups improved postprocedure. 3 months VAS and ODI better in PRF and RF groups. 6-months RF group stable in PRF group VAS increased. 1-y PRF group VAS and ODI as pretreatment. Analgesic use at 1 y. Sham > PRF > RF |
| Kroll et al. [ | RF vs PRF | 50 pts treated | 26 for follow-up | RF: 13; PRF: 13 | VAS; ODI | 3 months | VAS and ODI sign. improved at 3 months in RF group. Changes in PRF group not sign. |
| Nath et al. [ | RF vs sham | 376 | 40 | RF: 20; sham: 20 | GPE; pain relief, range of motion; QoL | 4 and 12 weeks | Sign. improvement of GPE in RF group, and pain reduction vs baseline and compared to sham. Secondary outcome sign. improvement in RF group |
GPE— Global Perceived Effect; max—maximum; ODI— Oswestry Disability Index; PRF—pulsed radiofrequency; pts—patients; QoL—quality of life; resp—respectively; RF—radiofrequency; RM—Roland-Morris disability questionnaire; SF-36—Short Form 36 Health Survey; sign.—significant; VAS—visual analogue scale